CDK4 and prostate cancer: Whether the AR-mediated cellular growth seen in prostate cancer cells as well as other dysregulated cellular functions such as PI3K/AKT pathway activity and DNA repair dysfunction render prostate cancers susceptible to CDK4/6 inhibition is an open question.